Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational ...
Dexcom G7 Continuous Glucose Monitoring System Will Be Available to Medicare Beneficiaries at Launch
SAN DIEGO--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today its next-generation Dexcom G7 CGM System ...
Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use ...
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today that Health Canada ...
The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...
Compare Apple Watch CGM apps for blood sugar readings, including Dexcom G7, FreeStyle Libre, and Eversense watch support.
The "direct-to-watch" feature eliminates the need to keep your phone near for readings. Dexcom is looking into other smartwatches too, the company's COO says. Jessica was a writer on the Wellness team ...
Once paired, you’ll be able to leave your iPhone behind while still getting real-time readings. Once paired, you’ll be able to leave your iPhone behind while still getting real-time readings. is a ...
Compare the Apple Watch, Samsung Galaxy Watch, and Pixel Watch for blood sugar tracking, CGM alerts, health trends, battery ...
Dexcom G7 is available for people with all types of diabetes ages two years and older, giving more Canadians than ever access to a simple, accurate 1 and effective diabetes management solution BURNABY ...
Users can go to dexcom.com/theft-check for information on how to determine if sensors are from the affected lots and what ...
Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results